Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post on X:
“I want to give thanks to the FDA, at Memorial Cancer Institute we got today 3 INDs approved at the same time for patients with HER2 mutations and lung cancer to start zongertinib! If we can continue working this way we can benefit a lot of patients.”
More posts featuring Luis E. Raez.